Already in the early 1960s, researchers noted the potential of mitochondria to take up large amounts of Ca2+. However, the physiological role and the molecular identity of the mitochondrial Ca2+ uptake mechanisms remained elusive for a long time. The identification of the individual components of the mitochondrial calcium uniporter complex (MCUC) in the inner mitochondrial membrane in 2011 started a new era of research on mitochondrial Ca2+ uptake. Today, many studies investigate mitochondrial Ca2+ uptake with a strong focus on function, regulation, and localization of the MCUC. However, on its way into mitochondria Ca2+ has to pass two membranes, and the first barrier before even reaching the MCUC is the outer mitochondrial membrane (OMM). The common opinion is that the OMM is freely permeable to Ca2+. This idea is supported by the presence of a high density of voltage-dependent anion channels (VDACs) in the OMM, forming large Ca2+ permeable pores. However, several reports challenge this idea and describe VDAC as a regulated Ca2+ channel. In line with this idea is the notion that its Ca2+ selectivity depends on the open state of the channel, and its gating behavior can be modified by interaction with partner proteins, metabolites, or small synthetic molecules. Furthermore, mitochondrial Ca2+ uptake is controlled by the localization of VDAC through scaffolding proteins, which anchor VDAC to ER/SR calcium release channels. This review will discuss the possibility that VDAC serves as a physiological regulator of mitochondrial Ca2+ uptake in the OMM.
Voltage dependent anion channel 2 (VDAC2) is an outer mitochondrial membrane porin known to play a significant role in apoptosis and calcium signaling. Abnormalities in calcium homeostasis often leads to electrical and contractile dysfunction and can cause dilated cardiomyopathy and heart failure. However, the specific role of VDAC2 in intracellular calcium dynamics and cardiac function is not well understood. To elucidate the role of VDAC2 in calcium homeostasis, we generated a cardiac ventricular myocyte-specific developmental deletion of Vdac2 in mice. Our results indicate that loss of VDAC2 in the myocardium causes severe impairment in excitation-contraction coupling by altering both intracellular and mitochondrial calcium signaling. We also observed adverse cardiac remodeling which progressed to severe cardiomyopathy and death. Reintroduction of VDAC2 in 6-week-old knock-out mice partially rescued the cardiomyopathy phenotype. Activation of VDAC2 by efsevin increased cardiac contractile force in a mouse model of pressure-overload induced heart failure. In conclusion, our findings demonstrate that VDAC2 plays a crucial role in cardiac function by influencing cellular calcium signaling. Through this unique role in cellular calcium dynamics and excitation-contraction coupling VDAC2 emerges as a plausible therapeutic target for heart failure.
Background and Purpose: Treatment of cardiac arrhythmia remains challenging due to severe side effects of common anti‐arrhythmic drugs. We previously demonstrated that mitochondrial Ca2+ uptake in cardiomyocytes represents a promising new candidate structure for safer drug therapy. However, druggable agonists of mitochondrial Ca2+ uptake suitable for preclinical and clinical studies are still missing.Experimental Approach: Herewe screened 727 compounds with a history of use in human clinical trials in a three‐step screening approach. As a primary screening platform we used a permeabilized HeLa cell‐based mitochondrial Ca2+ uptake assay. Hits were validated in cultured HL‐1 cardiomyocytes and finally tested for anti‐arrhythmic efficacy in three translational models: a Ca2+ overload zebrafish model and cardiomyocytes of both a mouse model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and induced pluripotent stem cell derived cardiomyocytes from a CPVT patient.Key Results: We identifiedtwo candidate compounds, the clinically approved drugs ezetimibe and disulfiram, which stimulate SR‐mitochondria Ca2+ transfer at nanomolar concentrations. This is significantly lower compared to the previously described mitochondrial Ca2+ uptake enhancers (MiCUps) efsevin, a gating modifier of the voltage‐dependent anion channel 2, and kaempferol, an agonist of the mitochondrial Ca2+ uniporter. Both substances restored rhythmic cardiac contractions in a zebrafish cardiac arrhythmia model and significantly suppressed arrhythmogenesis in freshly isolated ventricular cardiomyocytes from a CPVT mouse model as well as induced pluripotent stem cell derived cardiomyocytes from a CPVT patient.Conclusion and Implications: Taken together we identified ezetimibe and disulfiram as novel MiCUps and efficient suppressors of arrhythmogenesis and as such as, promising candidates for future preclinical and clinical studies.
1 November 2025 in Circulation: Arrhythmia and Electrophysiology
BACKGROUND: BMP10 (bone morphogenetic protein 10) is a ligand of the TGF (transforming growth factor) β superfamily secreted mainly by atrial cardiomyocytes. Elevated BMP10 blood concentrations predict atrial fibrillation (AF), AF recurrence after ablation, and AF-related cardiovascular complications like stroke. The conditions increasing BMP10 secretion and the downstream effects of BMP10 in cardiomyocytes are poorly understood. We assessed BMP10 secretion dynamics and BMP10 effects in a human 3-dimensional model of atrial and ventricular engineered heart tissue (EHT). METHODS: Cardiomyocytes (atrial and ventricular) differentiated from human induced pluripotent stem cells were cast into a fibrin-matrix to generate EHT. Atrial EHTs were optogenetically paced (3–5 Hz) or maintained at intrinsic beating rate for 24 hours up to 15 days. Release of BMP10 and other cardiac biomarkers from EHT was quantified. BMP10 plasma concentrations were compared between 1370 patients with different atrial rhythms at blood draw. Additionally, ventricular EHTs were exposed to BMP10 for 10 days. RESULTS: Atrial but not ventricular EHT released BMP10 within 48 hours of culture. High-rate optogenetic pacing increased atrial EHT BMP10 release by ≈3-fold after a latency of at least 24 hours post initiation of pacing. BMP10 plasma concentrations were elevated in patients with documented AF compared with sinus rhythm and even higher in patients with current AF. BMP10 induced upregulation of TGFβ pathway transcripts, increased expression of genes related to AF and heart failure, including PITX2 and NPPB , and increased relative contraction times in ventricular EHTs. CONCLUSIONS: High atrial rates elevate BMP10 expression and release, and higher plasma concentrations of BMP10 are observed in patients with active AF. BMP10 exposure induces transcriptomic changes linked to AF and heart failure in ventricular EHT. These findings support BMP10 as a biomarker and potential mediator of AF-related remodeling and tachycardiomyopathy.
The Na + /Ca 2+ exchanger (NCX) transports Ca 2+ and Na + through the plasma membrane of cardiomyocytes. NCX dysregulation has been related to diastolic dysfunction. NCX inhibition has been identified as a potential therapeutic approach. It can accelerate the decay of the cytosolic Ca 2+ concentration ([Ca 2+ ] i ) and improve impaired cardiomyocyte relaxation. We hypothesized that this counterintuitive effect is explained by the subcellular arrangement of NCX and local ion gradients within the intracellular Ca 2+ release units. In a parallel model‐based and experimental approach, we re‐evaluated the location of NCX with regard to the dyadic cleft and its role in modulating [Ca 2+ ] i . Stimulated emission depletion imaging revealed NCX in close proximity to junctophilin (the marker for the dyadic cleft). We simulated [Ca 2+ ] dynamics in the dyadic cleft considering Ca 2+ channels, NCX molecules and local concentration gradients. Positioning NCX inside the dyadic cleft in our computational model matched its action on spark rate. In forward mode (Ca 2+ out, Na + in) NCX decreased spontaneous Ca 2+ release events (spark rate) in simulations and imaging experiments, while in reverse mode it increased them. In paced cardiomyocytes, NCX inhibition consistently increased diastolic [Ca 2+ ]. The effects of NCX inhibition on transient amplitude and peak, however, depended on extracellular [Ca 2+ ] o suggesting a role of reverse‐mode NCX activity at high [Ca 2+ ] o . NCX inhibition prolonged the early rise of [Ca 2+ ], corroborating that reverse‐mode NCX facilitates the rapid initial increase of [Ca 2+ ] i during excitation. Our combined imaging, modelling and functional data support the hypothesis that NCX resides in the dyadic cleft where it bidirectionally shapes Ca 2+ transients and spark activity. image Key points: Our data suggest that Na + /Ca 2+ exchanger (NCX) is localized inside the dyadic cleft in cardiomyocytes, close to junctophilin, as shown by stimulated emission depletion imaging. Computational modelling confirmed NCX's dyadic positioning. It is critical for its effects on local Ca 2+ signalling. NCX bidirectionally modulates Ca 2+ dynamics: forward mode reduces, reverse mode increases spontaneous Ca 2+ sparks. NCX inhibition raises diastolic cytosolic Ca 2+ and alters Ca 2+ transient amplitude depending on extracellular Ca 2+ levels. Reverse‐mode NCX facilitates rapid initial Ca 2+ rise during excitation, highlighting its role in cardiac Ca 2+ regulation and potential therapy.